Pfizer’s maternal respiratory syncytial virus (RSV) vaccine was found to be highly effective in infants' first 6 months of life; survey shows long COVID-19 is more common among women than men; some voters worry that a Republican-controlled Congress could put science and science policy on the line.
Pfizer announced that its maternal respiratory syncytial virus (RSV) vaccine given during pregnancy protected infants from developing severe RSV symptoms during the first 6 months after birth. The vaccine was 81.8% effective against severe lower respiratory tract illness due to RSV in infants from birth through the first 3 months of life, and 69.4% effective through the first 6 months of life. The Washington Post reported that the data have not yet been peer reviewed or published outside the Pfizer news release, but they reflect good news during an early RSV season that is overwhelming pediatric hospitals. Pfizer plans to submit the vaccine for FDA approval by the end of 2022 with hopes to make it available by next winter.
Data from that US Census Bureau and National Center for Health Statistics show that long COVID-19 is more common among women than men, CNBC reported. According to results of a national survey completed by more than 41,000 US adults, more than 17% of women had long COVID-19 at some point since the beginning of the pandemic, compared with 11% of men. Additionally, around 2.4% of women with long COVID-19 experienced symptoms that significantly limited their normal activities, compared with 1.3% of men. Overall, more than 14% of US adults had long COVID-19 at some point, and 7% currently have it.
With midterm elections coming up next week, some voters are concerned that Congress chambers controlled by Republicans would put science on the line. STAT News reported that vocal critics of scientists and science agencies are expected to take on powerful Congressional committee positions if Republicans gain control, enabling them to “conduct sweeping investigations and put health officials on public trial.” These new positions may also give Republican officials the power to cut health agency budgets and deny funding for new COVID-19 measures and other health priorities. Additionally, some of the Republican party’s biggest defenders of science and science policy are set to retire.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More